160 related articles for article (PubMed ID: 31963693)
21. Synthesis of novel heterocyclic oleanolic acid derivatives with improved antiproliferative activity in solid tumor cells.
Leal AS; Wang R; Salvador JA; Jing Y
Org Biomol Chem; 2013 Feb; 11(10):1726-38. PubMed ID: 23381885
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.
El-Gamal MI; Khan MA; Tarazi H; Abdel-Maksoud MS; Gamal El-Din MM; Yoo KH; Oh CH
Eur J Med Chem; 2017 Feb; 127():413-423. PubMed ID: 28088086
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, structures, and selective toxicity to cancer cells of gold(I) complexes involving N-heterocyclic carbene ligands.
Boselli L; Ader I; Carraz M; Hemmert C; Cuvillier O; Gornitzka H
Eur J Med Chem; 2014 Oct; 85():87-94. PubMed ID: 25078312
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and Antiproliferative Activity of Novel Heterocyclic Glycyrrhetinic Acid Derivatives.
Alho DPS; Salvador JAR; Cascante M; Marin S
Molecules; 2019 Feb; 24(4):. PubMed ID: 30791593
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and antiproliferative activity of ligerin and new fumagillin analogs against osteosarcoma.
Blanchet E; Vansteelandt M; Le Bot R; Egorov M; Guitton Y; Pouchus YF; Grovel O
Eur J Med Chem; 2014 May; 79():244-50. PubMed ID: 24742383
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
29. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
[TBL] [Abstract][Full Text] [Related]
30. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
31. Carbonic anhydrase inhibitors. Synthesis of heterocyclic 4-substituted pyridine-3-sulfonamide derivatives and their inhibition of the human cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
Sławiński J; Szafrański K; Vullo D; Supuran CT
Eur J Med Chem; 2013 Nov; 69():701-10. PubMed ID: 24095761
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of 9-Hydroxystearic Acid Derivatives and Their Antiproliferative Activity on HT 29 Cancer Cells.
Calonghi N; Boga C; Telese D; Bordoni S; Sartor G; Torsello C; Micheletti G
Molecules; 2019 Oct; 24(20):. PubMed ID: 31619025
[TBL] [Abstract][Full Text] [Related]
33. Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
Kadela-Tomanek M; Bębenek E; Chrobak E; Marciniec K; Latocha M; Kuśmierz D; Jastrzębska M; Boryczka S
Eur J Med Chem; 2019 Sep; 177():302-315. PubMed ID: 31158746
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and Biological Evaluation of Novel Heterocyclic Imines Linked Coumarin- Thiazole Hybrids as Anticancer Agents.
Goud NS; Ghouse MS; Vishnu J; Pranay J; Alvala R; Talla V; Qureshi IA; Alvala M
Anticancer Agents Med Chem; 2019; 19(4):557-566. PubMed ID: 30734685
[TBL] [Abstract][Full Text] [Related]
35. Novel histone deacetylase inhibitors bearing a 4-piperidin-4-yl-triazole scaffold as antitumor agents.
Wang Y; Su L; Wang Q; Zhang L; Luan Y
Drug Dev Res; 2020 Feb; 81(1):52-61. PubMed ID: 31580523
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
37. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
[TBL] [Abstract][Full Text] [Related]
38. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
Zhang YB; Wang XL; Liu W; Yang YS; Tang JF; Zhu HL
Bioorg Med Chem; 2012 Nov; 20(21):6356-65. PubMed ID: 23018096
[TBL] [Abstract][Full Text] [Related]
40. Design, Synthesis and Evaluation of Novel 3/4-((Substituted benzamidophenoxy) methyl)-N-hydroxybenzamides/propenamides as Histone Deacetylase Inhibitors and Antitumor Agents.
Anh DT; Thuan NT; Hai PT; Huong LT; Yen NTK; Han BW; Park EJ; Choi YJ; Kang JS; Hue VTM; Han SB; Nam NH
Anticancer Agents Med Chem; 2019; 19(4):546-556. PubMed ID: 30426904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
